Alexion Wins Expanded Approval for Blockbuster Drug Soliris | BioSpace
Alexion dodges Soliris biosimilar bullet—for now—with Amgen patent settlement | Fierce Pharma
European marketing authorisation for Kanuma™
AstraZeneca gets EU clearance on Alexion - P.M. News
Alexion Pharmaceuticals
Alexion clears acquisition hurdles; Thetis gets $1.9M grant; Precipio signs European distribution deal | New Haven BIZ
Articles about Alexion
alexion – EJP RD – European Joint Programme on Rare Diseases
Alexion to expand biologics manufacturing with €65m investment
Alexion Pharmaceuticals: Revising My Valuation (NASDAQ:ALXN) | Seeking Alpha
AstraZeneca Alexion's Ultomiris approved in Europe for gMG - DirectorsTalk Interviews
Alexion - HB Design
AstraZeneca stock tumbles as Alexion shares soar after companies agree on takeover deal - MarketWatch
Matthew Wuhrer on LinkedIn: Senior Medical Director, Clinical Development Sciences - Alexion Careers
Alexion to Build New Offices - WSJ
Alexion
Alexion
AZ's rare disease Ultomiris snags 3rd FDA nod
Alexion Irish Factory Gets A $68.7M Upgrade From AstraZeneca | World Pharma Today
AstraZeneca's acquisition of Alexion cleared in Europe (NASDAQ:ALXN) | Seeking Alpha
UK regulator reviewing AstraZeneca's $39 bln Alexion buyout | Reuters
AstraZeneca's Alexion Splurge Could Attract a Crowd - WSJ
AstraZeneca completes $39bn acquisition of Alexion Pharmaceuticals
Bettina Nauli, Ph.D. – VP Central & Northern Europe at Alexion, AstraZeneca Rare Disease – AstraZeneca | LinkedIn
Alexion
Medica RCP | Companies |Alexion Pharma
UK Says 'Not So Fast' on AstraZeneca's $39 Billion Alexion Acquisition | BioSpace
